Clinical Trial Update: Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use

View source ↗

Summary

A study evaluating the safety and efficacy of Cubicin (daptomycin) under real-use conditions has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Complicated Skin and Skin Structure Infections
• Infective Endocarditis
• Right-sided Infective Endocarditis

Drugs mentioned

• Cubicin (daptomycin)

Snippet

Sponsor: AstraZeneca | Conditions: Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis | Status: WITHDRAWN